


AMENDMENT TO THE CLAIMS

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims:

1. (Original) A pharmaceutical composition for improving brain functions comprising a triterpene compound represented by the Formula 1 as an active ingredient:


[Formula 1]



wherein R_1 , R_2 and R_4 are independently CH_3 and R_3 is H; R_1 and R_2 are independently CH_3 , R_3 is H and R_4 is CH_2OH ; or R_1 , R_3 and R_4 are independently CH_3 and R_2 is H; and a pharmaceutically acceptable carrier or excipient.

2. (Currently amended) ~~An agent for improving brain functions,~~ A pharmaceutical composition for treating mild cognitive impairment and dementia which comprises as an active ingredient a triterpene compound represented by the Formula 1: ~~control~~

[Formula 1]



wherein R_1 , R_2 and R_4 are independently CH_3 and R_3 is H; R_1 and R_2 are independently CH_3 , R_3 is H and R_4 is CH_2OH ; or R_1 , R_3 and R_4 are independently CH_3 and R_2 is H; and a pharmaceutically acceptable carrier or excipient.

3-5. (Cancelled)

6. (New) The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient is a mixture of lactose, crystalline cellulose and magnesium stearate.

7. (New) The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient is a mixture of mannitol, $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ and distilled water.


8. (New) The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient is a mixture of ginseng extract, green tea extract, vitamin C, vitamin E, ferrous lactate, zinc oxide, nicotinic amide, vitamin A, vitamin B₁, vitamin B₂, corn starch and magnesium stearate.

9. (New) The pharmaceutical composition of claim 2, wherein the triterpene compound is hederagenin.

10. (New) The pharmaceutical composition of claim 2, wherein the triterpene compound represented by the Formula 1 is a mixture of oleanolic acid, hederagenin and ursolic acid.

11. (New) A method of improving brain function which comprises administering to a patient in need thereof a pharmaceutical composition comprising a triterpene compound represented by the Formula 1 as an active ingredient:


[Formula 1]



wherein R_1 , R_2 and R_4 are independently CH_3 and R_3 is H; R_1 and R_2 are independently CH_3 , R_3 is H and R_4 is CH_2OH ; or R_1 , R_3 and R_4 are independently CH_3 and R_2 is H; and a pharmaceutically acceptable carrier or excipient.

12. (New) The method of treating mild cognitive impairment and dementia which comprises administering to a patient in need thereof a pharmaceutical composition comprising a triterpene compound represented by the Formula 1 as an active ingredient:

[Formula 1]



wherein R_1 , R_2 and R_4 are independently CH_3 and R_3 is H; R_1 and R_2 are independently CH_3 , R_3 is H and R_4 is CH_2OH ; or R_1 , R_3 and R_4 are independently CH_3 and R_2 is H; and

a pharmaceutically acceptable carrier or excipient.